# **WEST Search History**

DATE: Thursday, December 04, 2003

Set Name side by side	Query	Hit Count S	Set Name result set
DB=US	PT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
L74	L73 and particulate	19	L74
L73	L72 and biodegradable	68	L73
L72	L71 and lactide	89	L72
L71	L70 and vaccine	114	L71
L70	L69 and pylori	178	L70
L69	helicobacter and glycolide	190	L69
L68	L66 and glycolide	3	L68
L67	L66 and polymer	8	L67
L66	L62 and vaccine	50	L66
L65	L62 and polymer	23	L65
L64	L62 and lactide	6	L64
L63	L62 and poly lactide	9181	L63
L62	H.pylori	133	L62
<del>L</del> 61	L60 and IB-367	2	1L61
L60 🔍	L59 and ventilation	37	L60
L59	VAR	1377	L59
L58	IB-367 and VAP	2	L58
L57	IB-367	12	L57
L56	L55 and peroxide	5	L56
L55	L53 and surfactant	126	L55
L54	L53 and bioactive	5	L54
L53	L52 and tocopherol	126	L53
L52	L51 and ethanol	130	L52
L51	L50 and stearic	136	L51
L50	L46 and iodine	329	L50
L49	L48 and ethanol	9	L49
L48	L46 and capric	16	L48
L47	I 46 and phosphate ester	663462	L47
L46	L45 and bovine	956	L48
L/45	L42 and mastitis	2044	L45
/L44	L43 and l42	32	L44

Generate Collection Print

## Search Results - Record(s) 11 through 19 of 19 returned.

L73 and particulate	9		
Terms Documents			
Generate Collection Print			
19. <u>6086901</u> , 29 Jan 98; 11 Jul 00. Use of microparticles combined with submicron emulsions. O'Hagan; Derek, et al. 424/283.1; 424/204.1 424/228.1 424/278.1 424/497 424/70.19. A61K039/29 A61K007/08 A61K045/00 A61K047/44.			
18. <u>6306405</u> . 02 May 00; 23 Oct 01. Use of microparticles combined with submicro oil-in-water emulsions. O'Hagan; Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1. A A61K039/12 A61K039/29.			
17. 6458370 20 Aug 01; 01 Oct 02. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan; Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1 424/70.11 424/70.19 435/4 435/5 435/6. A61K039/00 A61K045/00 C12Q001/00 C12Q001/70 C12Q001/68.			
16. <u>6514503</u> . 09 Jul 98; 04 Feb 03. Antigen delivery system. Gizurarson; Sveinbjorn 424/278.1; 424/184.1 424/234.1 514/2. A61K045/00 A61K047/00 A61K039/02.	, et al.		
15. <u>6534064</u> . 10 Oct 00; 18 Mar 03. Stabilized protein particles for inducing cellular responses. O'Hagan; Derek, et al. 424/205.1; 424/199.1 424/204.1 424/207.1 424/208.1 424/228.1 424/229.1 424/70.14 424/70.16 424/9.34 435/8 518/726. A61K039/12 A61K039 C07B063/06 C12Q001/70 C07C047/06.	/225.1		
14. <u>6623764</u> . 31 Aug 99; 23 Sep 03. <u>Biodegradable</u> targetable microparticle delivery Sokoll; Kenneth K., et al. 424/501; 424/78.37 528/318 528/329.1. A61K009/16 A61K047/3 C08G063/08.	•		
13. <u>20020025329</u> . 20 Aug 01. 28 Feb 02. Use of microparticles combined with submoil-in-water emulsions. O'Hagan, Derek, et al. 424/278.1; 424/204.1 424/228.1 424/280.1 424/497 424/70.11 424/70.19 424/70.9 A61K009/16 A61K009/50 A61K007/06 A61K007/06 A61K039/12 A61K045/00 A61K047/00.	4/283.1		
12. <u>20020136776</u> . 28 Sep 01. 26 Sep 02. Microparticle compositions and methods f manufacture thereof. Fang, Jia-Hwa, et al. 424/501; 424/70.11 424/94.1 514/44 A61K048/0461K038/43 A61K007/11 A61K009/50 A61K007/06.			
11. <u>20020197321</u> . 29 Apr 02. 26 Dec 02. Solid dispersing <u>vaccine</u> composition for one Seager, Harry. 424/486; A61K009/14.	ral delivery.		
2000000 2000000000000000000000000000000			

<u>Previous Page</u> <u>N</u>

Next Page

ı

Generate Collection Print

## Search Results - Record(s) 1 through 10 of 19 returned.

1. 20030211122 . 12 Jun 03. 13 Nov 03. Mucosal microparticle conjugate vaccine. Sjoholm, Ingvar, et al. 424/258.1; A61K039/112.
2. <u>20030170273</u> . 03 Oct 02. 11 Sep 03. Adjuvant compositions. O'Hagan, Derek, et al. 424/225.1; 424/130.1 424/199.1 435/6 514/44 A61K048/00 A61K039/395 C12Q001/68 A61K031/70 A01N043/04 A61K039/12 A61K039/29.
3. <u>20030138453</u> . 28 Sep 01. 24 Jul 03. Microparticles for delivery of heterologous nucleic acids. O'Hagan, Derek, et al. 424/199.1; 435/235.1 435/320.1 435/325 435/343 435/5 C12Q001/70 A61K039/12 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N005/00 C12N005/02 C12N005/06 C12N005/16.
4. <u>20030104067</u> . 08 Jan 03. 05 Jun 03. Method of obtaining cellular immune responses from proteins. O' Hagan, Derek, et al. 424/490; 424/186.1 424/188.1 424/189.1 A61K039/21 A61K039/29 A61K009/16 A61K009/50.
5. <u>20030099659</u> . 12 Jul 02. 29 May 03. Antigen delivery system. Gizurarson, Sveinbjorn, et al. 424/184.1; A61K039/00.
6. 20030082213. 02 Aug 02. 01 May 03. Use of microparticles combined with submicron oil-in-water emulsions. O'Hagan, Derek, et al. 424/278.1; 424/204.1 424/228.1 424/283.1 424/70.11 424/70.19 A61K007/06 A61K007/075 A61K039/12 A61K045/00 A61K047/44 A61K007/11 A61K007/08 A61K039/29 A61K047/00.
7. 20030078396. 06 Nov 01. 24 Apr 03. Compositions and methods for the detection, diagnosis and therapy of hematological malignancies. Gaiger, Alexander, et al. 536/23.1; C07H021/02 C07H021/04.
8. <u>20030072768</u> . 12 Nov 02. 17 Apr 03. Method to enhance an immune response of nucleic acid vaccination. Dalemans, Wilfried, et al. 424/185.1; 424/486 514/44 A61K048/00 A61K039/38 A61K039/00 A61K009/14.
9. 20030072764 . 05 Apr 02. 17 Apr 03. Mucosal boosting following parenteral priming. O'Hagan, Derek. 424/184.1; A61K039/00.
10. <u>20020198362</u> . 01 Mar 01. 26 Dec 02. Compositions and methods for the detection, diagnosis and therapy of hematological malignancies. Gaiger, Alexander, et al. 530/350; 435/320.1 435/325 435/6 435/69.1 536/23.1 C07K014/435 C12Q001/68 C07H021/04 C12P021/02 C12N005/06.
Generate Collection Print

Terms	Documents
L73 and particulate	19

Previous Page Next Page

## Generate Collection

L74: Entry 1 of 19

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211122

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211122 A1

TITLE: Mucosal microparticle conjugate vaccine

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME

CITY

STATE COUNTRY

RULE-47

Sjoholm, Ingvar

Uppsala

SE

Wikingsson, Lena Degling

Spanga

SE

US-CL-CURRENT: 424/258.1

#### CLAIMS:

- 1. Mucosal microparticle conjugate <u>vaccine</u> against a certain pathogenic microorganism, which comprises, as an immunizing component, a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to biodegradable microparticles.
- 2. <u>Vaccine</u> according to claim 1, wherein the <u>biodegradable</u> microparticles are starch particles, including cross-linked starch particles.
- 3. <u>Vaccine</u> according to claim 2, wherein the cross-linked starch particles are polyacryl starch microparticles.
- 4.  $\underline{\text{Vaccine}}$  according to any one of claims 1-3, wherein the mucosal  $\underline{\text{vaccine}}$  is an oral vaccine.
- 5. <u>Vaccine</u> according to any one of claims 1-4, wherein the pathogenic microorganism is an intracellular pathogenic microorganism.
- 6. <u>Vaccine</u> according to claim 5, wherein said intracellular pathogenic microorganism is selected from the group consisting of Mycobacterium tuberculosis and Salmonella enteritidis.
- 7. Method of inducing protective immunity against a certain pathogenic microorganism in a mammal, including man, comprising mucosal administration to said mammal of a T-cell activating amount of protection-generating antigens derived from said microorganism conjugated, possibly via a linker, to <a href="mailto:biodegradable">biodegradable</a> microparticles, as an immunizing component.
- 8. Method according to claim 7, wherein the mucosal administration is oral administration and the protection-generating antigens derived from said microorganism are secreted proteins from Mycobacterium tuberculosis or Salmonella enteritidis
- 9. Use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker, to  $\frac{\text{biodegradable}}{\text{vaccine}}$  microparticles for the production of a mucosal microparticle conjugate  $\frac{\text{vaccine}}{\text{vaccine}}$  against said certain pathogen.
- 10. Use according to claim 7, wherein the mucosal <u>vaccine</u> is an oral <u>vaccine</u>, said antigens derive from Mycobacterium tuberculosis or Salmonella enteritidis, and the <u>biodegradable</u> microparticles are starch particles, including cross-linked starch particles and polyacryl starch microparticles.

### Generate Collection

L74: Entry 1 of 19

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211122

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030211122 A1

TITLE: Mucosal microparticle conjugate vaccine

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME

CITY Uppsala

STATE

RULE-47

Sjoholm, Ingvar

SE

COUNTRY

Wikingsson, Lena Degling

Spanga

SE

ASSIGNEE-INFORMATION:

NAME

CITY STATE COUNTRY

TYPE CODE

INNOVENTUS PROJECT AB

03

APPL-NO: 10/-459525 [PALM] DATE FILED: June 12, 2003

RELATED-US-APPL-DATA:

Application 10/459525 is a division-of US application 09/623046, filed November 9,

2000, PENDING

Application 09/623046 is a a-371-of-international WO application PC/T/SE99/00277, filed February 26, 1999, UNKNOWN

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY

APPL-NO

DOC-ID

APPL-DATE

SE

9800615-8

1998SE-9800615-8

February 27, 1998

INT-CL: [07] A61 K 39/112

US-CL-PUBLISHED: 424/258.1 US-CL-CURRENT: 424/258.1

### ABSTRACT:

Mucosal, particularly oral, microparticle conjugate vaccines against certain pathogenic microorganisms, especially intracellular pathogenic microorganisms, are disclosed. An immunizing component of such a vaccine comprises protection-generating antigens derived from a certain pathogenic microorganism, such as Mycobacterium tuberculosis or Salmonella enteritidis, conjugated, possibly via a linker, to biodegradable microparticles, particularly starch microparticles, such as cross-linked starch microparticles, e.g. polyacryl starch microparticles. Further, a method of inducing protective immunity against a certain pathogenic microorganism in a mammal, and the use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine are described.

Generate Collection Print		
Search Results - Record(s) 1 through 6 of 6 returned.		
1. <u>20030049698</u> . 08 Oct 02. 13 Mar 03. Diagnosis and treatment of gastrointestinal disease. Vang, Timothy C 435/7.21; 435/7.32 G01N033/567 G01N033/554 G01N033/569.		
J 2. <u>20020146423</u> . 23 Dec 97. 10 Oct 02. PROTECTIVE HELICOBACTER ANTIGENS. OIDGE, CHRISTOPHER VINCENT, et al. 424/184.1; A61K039/00 A61K039/38.		
3. <u>20020122794</u> . 09 Aug 96. 05 Sep 02. ANTIGENIC PREPARATION FOR TREATMENT R PREVENTION OF HELICOBACTER INFECTION. DOIDGE, CHRISTOPHER VINCENT. 24/130.1; A61K039/395.		
4. <u>6630582</u> . 07 Jan 98; 07 Oct 03. Treatment and prevention of helicobacter infection. Doidge; hristopher V., et al. 536/23.6; 424/234.1 424/93.2 435/192 435/7.32. C07H021/04.		
5. <u>6468545</u> . 20 Oct 99; 22 Oct 02. Treatment and prevention of helicobacter infection. Doidge; hristopher V., et al. 424/234.1; 435/252.1 435/34 435/69.1 536/23.4 536/23.5. A61K039/02.		
6. 6129923. 29 Oct 98; 10 Oct 00. Treatment of H. pylori associated gastroduodenal disease. oidge; Christopher Vincent, et al. 424/234.1; 424/194.1 536/23.1. A61K039/02.		
Generate Collection Print		

Terms Documents

L62 and lactide 6

Previous Page Next Page

Generate Collection Print

	Search Results - Record(s) 1 throu	igh 10 of 23 returned.
	20030162691 . 10 Mar 03. 28 Aug 03. Novel ant A61K031/00 C12N001/21.	timicrobial therapies. Kornberg, Arthur. 514/1;
LT-A TOX	20030113338. 27 Apr 99. 19 Jun 03. IMMUNO KIN. PIZZA, MARIAGRAZIA, et al. 424/184.1; 18 C07K001/00.	
*******	20030049698. 08 Oct 02. 13 Mar 03. Diagnosis nothy C., 435/7.21; 435/7.32 G01N033/567 G011	<del>-</del>
Tian, Jing-	20020107368 . 06 Dec 00. 08 Aug 02. Helicobac Hui, et al. 530/388.4; 424/190.1 530/350 536/23 00 C07K017/00 C07K016/00 C12P021/08.	· · · ·
structure d	20020090631. 14 Nov 01. 11 Jul 02. Method for lata. Gough, David A., et al. 435/6; 435/7.1 702/ 00 G01N033/48 G01N033/50.	
	20020081686 . 28 Jun 01. 27 Jun 02. Novel antin 124/93.4 424/93.47 424/93.48 435/212 C12N009	
	20020051819. 15 Jun 01. 02 May 02. Peptides, oderia cepacia. Kuhner, Carla H., et al. 424/484; 4/08.	
human sen	20020045195. 12 Oct 01. 18 Apr 02. Method fo um by the use of lateral flow assays. Hubscher, T. 53 G01N033/542 C12M001/34 G01N033/558.	
	6610504. 10 Apr 00; 26 Aug 03. Methods of deting a mutant SAH hydrolase. Yuan; Chong-Sheng	
10. helicobacte A61K039/	6585975. 01 Nov 99; 01 Jul 03. Use of Salmon er infection. Kleanthous; Harold, et al. 424/200.1; 02.	9
***************************************	Generate Collection	Print
	Terms	Documents
	L62 and polymer	23
	1 P	

12/4/03	9:57	PM
---------	------	----

Previous Page Next Page

Generate Collection	Print

## Search Results - Record(s) 21 through 23 of 23 returned.

- 21. CN 1397283 A WO 9638186 A1 AU 9657557 A AU 701974 B BR 9609166 A CN 1186436 A. Novel chemotherapeutic compsns. to treat cancer comprise polymeric and/or copolymeric compsns. to treat also gastrointestinal disease, diarrhoea, increases weight in humans, animals and birds. MELROSE, G J H. A23K001/16 A61K031/765 A61P035/00 C08G077/42 C08L029/00 C08L029/14 C08L033/02.
- 22. WO 9605822 A1 US 5534544 A. Use of surfactants and emulsifying agents to inhibit Helicobacter pylori and treatment of infection by sequential admin of antibiotic then surfactant or emulsifying agent free of calcium, magnesium, aluminium or silicon ions. KANE, A V, et al. A61K031/23 A61K031/34.
- 23. WO 9532414 A1. Strip device for detection of antibody analytes using a receptor specific for a conserved region of the antibody conjugated to a directly detectable label. GOVINDARAJAN, A G, et al. G01N021/00 G01N033/53 G01N033/543 G01N033/544 G01N033/552 G01N033/553.

Generate Collection

Print

	rms	Documents
L62 and polymer		23

Previous Page No

Next Page

L62 and polymer

Print Generate Collection

	Search Results - Record(s) 3 throu	gn 12 of 23 returned.
	20030049698. 08 Oct 02. 13 Mar 03. Diagnosis nothy C 435/7.21; 435/7.32 G01N033/567 G011	_
Tian, Jing-	20020107368 . 06 Dec 00. 08 Aug 02. Helicobac Hui, et al. 530/388.4; 424/190.1 530/350 536/23. 00 C07K017/00 C07K016/00 C12P021/08.	
structure d	20020090631. 14 Nov 01. 11 Jul 02. Method for lata. Gough, David A., et al. 435/6; 435/7.1 702/100 G01N033/48 G01N033/50.	
******	20020081686. 28 Jun 01. 27 Jun 02. Novel antin 424/93.4 424/93.47 424/93.48 435/212 C12N009/	<u> </u>
	20020051819. 15 Jun 01. 02 May 02. Peptides, oderia cepacia. Kuhner, Carla H., et al. 424/484; 4/08.	
human ser	20020045195. 12 Oct 01. 18 Apr 02. Method for um by the use of lateral flow assays. Hubscher, Tl 6/53 G01N033/542 C12M001/34 G01N033/558.	•
	6610504. 10 Apr 00; 26 Aug 03. Methods of det ing a mutant SAH hydrolase. Yuan; Chong-Sheng	· · · · · · · · · · · · · · · · · · ·
10. helicobacto A61K039/	6585975. 01 Nov 99; 01 Jul 03. Use of Salmon er infection. Kleanthous; Harold, et al. 424/200.1; 702.	
pseudomo	6551795. 18 Feb 99; 22 Apr 03. Nucleic acid an nas aeruginosa for diagnostics and therapeutics. R 435/325 435/6 536/23.1 536/23.7. C12P021/06 0	Rubenfield; Marc J., et al. 435/69.1; 435/253.3
	6528325. 13 Oct 00; 04 Mar 03. Method for thum by the use of lateral flow assays. Hubscher; Tl 435/287.7 435/7.1 435/7.94 436/513 436/514. G	nomas T., et al. 436/518; 422/56 422/58
	Generate Collection	Print
	Terms	Documents

12/4/03 10:00	PM (
---------------	------

23